Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06145373 · ClinicalTrials.gov registry record · Phase 4
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
A Phase 4 study of Hemophilia A, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06145373: Recruiting Phase 4 study of Hemophilia A, sponsored by Sanofi.
NCT06145373 is a Phase 4 study of Hemophilia A that is actively recruiting participants, run by Sanofi. The registered enrollment target is 20 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06145373, a Phase 4 study of Hemophilia A, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis. This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥12 years, who were previously receiving emicizumab prophylaxis. Study details include: * The study duration will be up to approximately 28 months: * There will be an approximately 2-month screening period. * There will be an approximately 2-month period before fitusiran treatment starts (pre-fitusiran treatment period) * The fitusiran treatment duration will be up to 18-months (fitusiran treatment period) * The antithrombin (AT) follow-up (FU) period will be approximately 6 months after the last dose of fitusiran (during which the AT activity level will be monitored at approximately monthly intervals following the final fitusiran dose until AT activity levels return to at least 60%). * The study site visits are scheduled at monthly/ every 2 months intervals of 28 days (4 weeks) / 56 days (8 weeks), respectively, during the fitusiran treatment period.
Primary Outcome
Incidence, severity, and seriousness, of AEs occurred during fitusiran treatment period will be reported
Conditions Studied
Interventions
- BIOLOGICAL Clotting factor concentrates (CFC) or bypassing agents (BPA)
- BIOLOGICAL Antithrombin concentrate (ATIIIC)
- DRUG Fitusiran (SAR439774)
- BIOLOGICAL Emicizumab
Study Locations (2)
California
- Children's Hospital Los Angeles- Site Number : 8400005 - Los Angeles
Podlaskie
- Investigational Site Number : 1580001 - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 4 |
What NCT06145373 shows while recruiting
NCT06145373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 4 interventions - of which Clotting factor concentrates (CFC) or bypassing agents (BPA) is the first listed.
NCT06145373 reports a single indexed study location in California, Podlaskie.
Frequently Asked Questions
What is clinical trial NCT06145373 about?
NCT06145373 is a clinical study titled "A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab". This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis. This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study wi...
What is the current status of trial NCT06145373?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-03-01. Estimated completion is 2029-11-30.
What conditions does trial NCT06145373 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT06145373?
The interventions under investigation include: Clotting factor concentrates (CFC) or bypassing agents (BPA) (BIOLOGICAL), Antithrombin concentrate (ATIIIC) (BIOLOGICAL), Fitusiran (SAR439774) (DRUG), Emicizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06145373?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06145373 being conducted?
This trial has 2 study locations across California, Podlaskie. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06145373's enrollment target sits among peer trials
20 31st of 42 higher than 11 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
RECRUITING · Phase 4
-
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
COMPLETED · Phase 4
-
Prophylaxis Regimen for Hemophilia A Patients
COMPLETED · Phase 4
-
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
COMPLETED · Phase 4
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI